Soleno Therapeutics, Inc. (FRA:6XC)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.35B -34.9% |
| Revenue (ttm) | 162.17M |
| Net Income | 17.44M |
| EPS | 0.33 |
| Shares Out | n/a |
| PE Ratio | 77.22 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | n/a |
| Open | 26.88 |
| Previous Close | 26.58 |
| Day's Range | 25.52 - 26.92 |
| 52-Week Range | 25.52 - 76.65 |
| Beta | n/a |
| RSI | 34.43 |
| Earnings Date | May 8, 2026 |
About Soleno Therapeutics
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. [Read more]
News
AMG TimesSquare Small Cap Growth Fund Q4 2025 Performance Insights
The Fund rebounded and outperformed the Russell 2000 ® Growth Index in the fourth quarter. Boot Barn's revenues and earnings handily exceeded estimates, with greater transaction volumes and new store ...
Notice to Long-Term Investors of Soleno Therapeutics, Inc. (SLNO): Grabar Law Office Investigates Claims on Your Behalf
Philadelphia, Pennsylvania--(Newsfile Corp. - March 13, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SL...
SLNO Lawsuit Alleges Allegedly Conducting Sham Clinical Trials - Soleno Therapeutics, Inc. Investors Face Losses Following Allegedly Conducting Sham Clinical Trials: SueWallSt
Alert: Claims Focus on Alleged Misrepresentations About Clinical Trial Integrity and Drug Safety NEW YORK, March 12, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Soleno Therapeutic...
Soleno Therapeutics, Inc. (SLNO) Q4 2025 Earnings Call Transcript
Soleno Therapeutics, Inc. (SLNO) Q4 2025 Earnings Call Transcript
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...
Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism
REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses
SAN DIEGO , Dec. 15, 2025 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors vi...
Soleno Therapeutics Announces the Passing of Board Member William G. Harris
REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% – Hagens Berman
SAN FRANCISCO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) saw the price of their shares tumble $18.78 (-28%) after the company reported disappointing infor...
Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Soleno Therapeutics, Inc., (“Soleno" or the "Company") (NASDAQ: SLNO) investors that the firm has initiated an investigation...
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement
REDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare disease...
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKATÔ XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman
SLNO Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Nov. 7, 2025 /PRNewswire/ -- On November 5, 2025, investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) saw the price of ...
Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call Transcript
Soleno Therapeutics, Inc. ( SLNO) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Anish Bhatnagar - Chairman, President, CEO & COO Meredith Manning - Chief Commercial Officer ...
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...
Soleno Therapeutics to Participate in Upcoming November Conferences
REDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare disease...
Soleno: Blockbuster Launch In Progress
Soleno Therapeutics is reassessed after a 24% drop post-VYKAT XR approval enthusiasm. SLNO now faces the critical 'danger zone' between FDA approval and successful commercialization of VYKAT XR for Pr...
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman
SAN FRANCISCO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- On August 15, 2025, shares in Soleno Therapeutics, Inc. (NASDAQ: SLNO) experienced a significant drop following the release of a highly critical report...
SOLENO (SLNO) REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Soleno Therapeutics, Inc. and Encourages Investors to Contact the Firm
Scorpion Capital alleged Soleno's sole product, Vykat XR, was overpriced and unsafe for children, causing shares to drop 7.4% to $71.63 on August 15, 2025.
Soleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
OAKLAND, Calif.--(BUSINESS WIRE)---- $SLNO #SLNO--Gibbs Mura is investigating legal claims on behalf of investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO).
SLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $SLNO--SLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
Soleno reports death of patient who took genetic disorder treatment, shares fall
Soleno Therapeutics said on Wednesday it is aware of the death of a 17 year old male who was on the company's treatment for patients who experience feelings of intense and persistent hunger, sending i...
Soleno Therapeutics, Inc. (SLNO) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 1:30 PM EDT Company Participants Anish Bhatnagar - Chairman, President, CEO & COO James Ma...
Soleno Therapeutics, Inc. (SLNO) Presents At Cantor Global Healthcare Conference 2025 Transcript
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Cantor Global Healthcare Conference 2025 September 3, 2025 1:00 PM EDT Company Participants Anish Bhatnagar - Chairman, President, CEO & COO James MacKaness - ...
Soleno Therapeutics to Participate in Upcoming September Conferences
REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare disease...
Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe
Soleno Therapeutics Inc. SLNO shares fell on Friday following a short report from Scorpion Capital, which criticized the company's only product, Vykat XR, as overpriced and potentially unsafe for chil...